December 9-10, 2013 • Cambridge, MA USA
SAMPLE PREP EAST Conference is the 8th meeting in the Knowledge Foundation’s Sample Prep Conference Series - an internationally recognized meeting for experts in sample preparation technologies for detection, identification, diagnostics and analysis of biomedical, biological and chemical agents, substances and threats in point-of-care, laboratory and field settings will explore the latest R&D developments, ready-to-market technologies, and their applications by exploring the following topical areas:
- Robust methodologies for sample collection, (pre-)concentration, lysis, and target extraction
- Critical role of sample prep in early diagnostics
- Rapid sample-to-sequence techniques
- Point-of-care sampling, detection and analysis
- Sample preparation with microfluidics
- Sample prep-on-a-chip
- Robust sampling methodologies (automation, high-throughput, combinatorial approach in sample prep)
- Alternative amplification techniques for sensitive sample prep
- Sample preparation as a separate system vs. an integrated module approach
- End-user prospective for biodetection and sampling technologies and devices
- Alternative and disruptive approaches to sample preparation and applications
- Field-ready devices: compatibility/reliability/scalability
Novel robust sampling and bioforensic techniques will be reviewed as applicable to biodefense, field & point-of-care biomedical & clinical applications, food & water testing, and environmental & agricultural sampling. Our group of leading experts from government, academia and industry will address the following discussion issues and areas of focused technology development and implementation:
- Target enrichment and background depletion techniques
- Isolation of dilute objects on cell and molecular levels
- Immiscible phase purification
- Novel methods of extraction from tough (non-filterable) matrices
- Nucleic acid and protein based sample prep for next generation sequencing
- Nanotechnology and miniaturization challenges for sample preparation
- New assay and sequencing technologies for sample preparation, detection and analysis
- Standardization and regulatory issues in sample preparation across different applications
- Sample prep technologies for detection/diagnostics vs. pharma
Media Sponsors and Conference Partners
Monday, December 9, 2013
8:00 Registration, Exhibit Viewing/Poster Setup, Coffee and Pastries
8:50 Organizer’s Welcome and Opening Remarks
9:00 Sample Preparation Approaches for Orthogonal Data in Field Forward Diagnostics
Richard Allen, PhD, Senior Scientist, Biodefense and Food Safety, Luminex Corporation
Accurate assessments of complex infectious and chronic disease states present a unique instrumentation and assay challenge. Often the clinical presentation of an illness is the product of, or is impacted by, multiple competing factors that require widely differing analysis and preparation techniques to access. We are developing a digital microfluidic sample-to-answer system to address this limitation. For example, a key aspect of this technology is the ability to identify a pathogen through molecular techniques and simultaneously quantify host biomarkers over the infection time course via affinity capture reagents. Currently, portable systems provide one-dimensional data (e.g. sequence, biomarker). Our approach, combining multiple measurement modes from one sample has previously only been available to larger lab facilities. While we are only combining two types of tests (PCR assays and Immunoassays) in initial prototypes, this capability is unique in the current POC field and, in a field forward setting, these data will yield a more accurate and timely treatment, leading to better clinical outcomes than either test alone.
9:30 Automated Field Sample Preparation
Michael Connolly, PhD, CEO, Integrated Nano-Technologies
INT has developed the Palladium biological identification system for field use. It automates all steps of sample preparation, nucleic acid amplification and identification into a single disposable cartridge. Assays have been developed for pathogens in blood, sputum, insect vectors and environmental samples. The system can be used for identification and diagnostics or to prepare nucleic acids for analysis on other platforms such as DNA sequencers.
10:00 Rapid and Simple Procedure to Detect the Presence of Viruses and Mycoplasma in Cell Cultures Used in the Manufacture of Biotherapeutics
Kathleen Souza, PhD, Senior Research Scientist, EMD Millipore Corporation, a division of Merck KGaA*
Mammalian cell cultures used as a substrate in the production of biotherapeutics need to be free of contaminants in order to ensure product purity and safety. Many biotherapeutics are produced in rodent cells with raw materials of biological origin so they are susceptible to virus and mycoplasma contamination. Current cell-based methods for biocontaminant detection require days to weeks to obtain results. We have developed a sample preparation and detection procedure to capture contaminants, extract nucleic acids in order to detect a specific set of viruses and mycoplasma contained in CHO cells culture samples with a time to result of 4h, and a hands on time of 30 min. The combination of virus and mycoplasma detection in a single sample decrease the overall time from days to hours.
*In collaboration with: Manjula Aysola, Celine Rofel, Jonathan Broe, Nolwenn Marques, Bodo Holtkamp , Frédéric Marc
10:30 Networking Refreshment Break, Exhibit/Poster Viewing
11:00 Universal Multiplexed Blood Screening Platform with a Robotic System
Vincent Gau, PhD, President, GeneFluidics, Inc.
A 96-well frame plate capable of housing eight universal blood testing strips, multiplexed electrochemical sensor array, EK manipulation, two stage focusing flow channel and a blood cell counter with the robotic lab automation system is being developed. By leveraging established robotic and microfluidic expertise, we can utilize the superior accuracy and throughput of the robotic system and the parallel microfluidics channels of the point-of-care system. This hybrid robotic-microfluidics system can minimize human operation and potential contamination in an enclosed system that interfaces with microfluidic modules precisely handling blood samples of just a few µL.
11:30 Neutrophil Chemotaxis Assay from One Drop of Blood
Daniel Irimia, PhD, MD, Assistant Professor, Harvard Medical School
While the absolute neutrophil count is the most common blood tests in the clinic, it implicitly assumes that all neutrophils are normal and does not account for transient alterations of function. To estimate the risk for infections more accurately in patients with burn injuries, we designed a microfluidic device that measures neutrophil chemotaxis directly from one droplet of blood and employed it to identify interventions that restore normal neutrophil functions.
12:00 Acquisition of High Quality Tissues to Support Genome Wide Association Studies
Latarsha Carithers, PhD, Project Manager, Office of Biorepositories and Biospecimen Research, National Cancer Institute
The Genotype-Tissue Expression project is a NIH Common Fund
study that is aimed at understanding how genetic variation influences
gene expression in normal tissues. The purpose of this presentation is
to describe a biospecimen collection platform that was developed to
address the logistical challenges of acquiring a large collection of
high-quality tissues from rapid autopsy and organ donors that was needed
to support genome wide association analysis for this study.
12:30 Luncheon Sponsored by the Knowledge Foundation Membership Program
2:00 Automated Sample Prep for Personalized Medicine
Richard A. Montagna, PhD, Senior Vice President, Rheonix, Inc.
The presentation will focus on the challenges associated with providing cost-effective molecular diagnostics for personalized medicine and companion diagnostics in a manner that meets the needs of all stakeholders. The challenges facing clinical laboratories include the ability to simplify and streamline complex sample preparation steps and achieving actionable results in a timely manner. In addition, due to new molecular diagnostic reimbursement guidelines issued by CMS, it is imperative that cost-effective methods designed to meet the needs of all stakeholders be implemented. A fully automated molecular diagnostic platform will be described.
2:30 Sample Preparation for Molecular Diagnostics of Sexually Transmitted Infections
Wamadeva Balachandran, PhD, Depart of Systems Engineering, Brunel University, United Kingdom
An integrated microengineered platform is under development for automated DNA extraction, isothermal amplification and detection of sexually transmitted infections (STIs). Complex sample preparation techniques have inhibited the production of a true “sample-in answer-out” point of care test. This work aims to reduce the complexity associated with sample preparation by simplifying sample collection and nucleic acid extraction. Urine samples are collected and fed into a sample purification device with passive mixing of the lysis/binding buffer. DNA is extracted on a chitosan impregnated organic membrane within the microfluidic device. Chitosan has been shown to adsorb DNA in microfluidic devices by anion exchange. This method significantly reduces complexity associated with nucleic acid extraction; DNA is bound to the membrane under acidic conditions and eluted in alkaline conditions.
3:00 Automated On-Chip Bead-Based ELISA
Alexis Sauer-Budge, PhD, Senior Research Scientist, Fraunhofer Center for Manufacturing Innovation, Fraunhofer USA
We present a lab-on-a-chip and associated instrument for ELISA detection of proteins from liquid samples. The system performs all necessary steps in a fraction of the time required for standard off-chip protocols. The instrument automates control of the fluids via remote valve switching and detects fluorescence from reacted substrate. Using IL-10 as a model antigen, we show that our on-chip assays have comparable sensitivity to corresponding manual ELISAs in a much shorter timeframe.
3:30 Networking Refreshment Break, Exhibit/Poster Viewing
4:00 CyPlex: A Novel Platform for Multi-Analyte Immunoassays
Rajiv Pande, PhD, Vice President, CyVek Inc.
A new platform technology for multiplexed immunoassays is described. The technology combines a unique solid phase approach with innovative microfluidics to design test cartridges that can be configured in a variety of ways for applications in life science research and in clinical diagnostics. A key feature of CyPlex™ is that each analyte, from every sample, is assayed individually in its own microenvironment. So, while the test is multi-analyte, each assay is performed with its own specific reagents: there are no reagent cocktails, and chances of cross-reactivity are greatly diminished. Assays are fully automated. CyPlex™ assays are sensitive (fM), robust (precise and accurate), rapid (1 hr time to result), and require very low sample volumes (2 µL per analyte). We will describe a novel multi-analyte platform for performing quantitative immunoassays. Data from CyPlex™ assays will be presented to demonstrate the robustness, sensitivity, precision and accuracy of this technology.
4:30 Development of a Cell Based Functional Assay for the Detection of Botulinum Neurotoxin Type A & E
Shashi K. Sharma, Research Microbiologist, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration
The standard procedure for definitive detection of BoNT-producing Clostridia is a culture method combined with neurotoxin detection using a standard mouse bioassay. The mouse bioassay is highly sensitive and specific, but it is expensive and time-consuming and there are ethical concerns due to use of laboratory animals. Cell based assays provide an alternative for mouse bioassay in screening for BoNT-producing Clostridia. Here, we describe a cell-based assay utilizing a fluorescence reporter construct with full length SNAP-25 as the linker, expressed in a neuronal cell model, to study toxin activity in situ. Our data indicates that PC-12 cells have significant sensitivity to BoNT/A and E action and the assay can detect as little as 100 pM BoNT/A activity within living cells. Of the in vitro approaches published in the literature for BoNT detection, we believed that cell-based methods provide a model that more closely approximates the in vivo model and have a potential to at least reduce and refine animal assays if not replace it.
5:00 Exhibitor/Sponsor Showcase Presentations, Discussion
5:30 End of Day One
Tuesday, December 10, 2013
8:00 Exhibit/Poster Viewing, Coffee and Pastries
9:00 Biostabilization of Nucleic Acids for Next-Gen Sequencing
Rolf Muller, PhD, CEO, Biomatrica
There is an increasing need for the development of technologies for handling human specimens in an all ambient workflow at point-of-care, laboratory and field settings without sacrificing the quality of molecular analytes contained in patient samples. We have developed biostabilization methods for patient samples that allow a complete ambient diagnostic workflow. We now demonstrate that such biostabilized nucleic acids retain near-native quality and quantity compared to fresh samples and can also be used to obtain comprehensive genomic data by Next-Gen Sequencing analysis.
9:30 Electricity-Free, Hand-Held Chromatography Platform
David R. Pawlowski, PhD, Senior Research Scientist, CUBRC
CUBRC has developed an electricity-free chromatography platform conceptually based on disposable transfer pipettes. Our platform encompasses a chromatography resin or sorbent built into a low-density polyethylene transfer pipette and held within by a high-density polyethylene frit. CUBRC has successfully demonstrated solid phase nucleic acid and protein extraction using silica as the sorbent and His-tagged protein purification using Talon® (Clonetech) and His-bond® (Novagen) metal affinity resins. Our platform is designed to include other combinations such as antibody conjugates, aptamers, or nucleic acid oligomers. Custom combinations can also be built to suit a researcher’s individual requirements. This platform is particularly well suited for use in austere environments, teaching laboratories or University settings.
10:00 One Step cDNA
Synthesis from Biological Samples with ExiProgen Automated System
PhD, Director, Bioneer Inc.
Maintaining RNA integrity is
critical for obtaining meaningful data. In order to minimize the risk of RNA
degradation, it is critical to reduce RNA preparation time and proceed to cDNA
synthesis immediately. Bioneer’s ExiProgen allows for the extraction of high
quality RNA followed by cDNA synthesis in a single process and in a fully
automated format. The one-step process of ExiProgen is especially suitable for
cDNA prep as well as RNA analysis in microarray, qPCR and NGS-based assays. The
data presented displays how ExiProgen can provide minimal RNA degradation and
more intact cDNA synthesis from HeLa cells in contamination-free environment.
10:30 Networking Refreshment Break, Exhibit/Poster Viewing
11:00 Simplifying Sample Collection and Processing with Unique Device for Rapid POC Test
Michael A. Harvey, PhD, Chief Science Officer, Maine Manufacturing LLC
Client FABPulous came with a concept that had 6 sample collection and processing steps. We helped them simplify it down to 2 steps. This unique device collects a blood sample, separates plasma from whole blood, adds a reagent, and finally delivers it to a lateral flow strip. The device already has a CE mark and since it is so intuitive, it should be approved by the FDA and CLIA-waived soon.
11:30 FilmArray Panel for Detection of Gastrointestinal Pathogens in Stool
Stephanie Thatcher, Director of Systems Integration, and Jeremy Green, Researcher, BioFire Diagnostics, Inc.
BioFire Diagnostics has developed a new FilmArray panel designed to detect gastrointestinal pathogens in stool. The FilmArray is a sample-to-result system that automatically lyses organisms and purifies nucleic acids for multiplex PCR detection. The entire process, including detection, takes about an hour. The automated stool preparation system reliably isolates DNA and RNA from stool samples to detect the presence of a diverse set of about 20 GI pathogens, including bacterial, viral, and protozoan targets. Mechanical lysis is used to achieve efficient extraction of organisms, giving the FilmArray GI panel the ability to detect anything from a RNA virus to a sporulated oocyst. The highly varied nature of stool specimens was a unique challenge to low volume sample preparation. The solid particulates found in stool drove development of a new sample loading system. The integrated loading filtration system mitigates some of the negative effects of stool, while allowing all target pathogens to be detected. This system is applicable to other solid sample matrices that will be introduced into the FilmArray system in the future. Also, the use of nested multiplex PCR allows reliable pathogen detection, even at low levels, making the system less susceptible to the inhibitory impacts of stool. The FilmArray system is able to detect pathogenic organisms reliably in real world stool samples due to the success of the recovery of nucleic acids from a complex sample type with minimal processing (sample handling takes less than 2 minutes).
12:00 Thermostable Positive Controls
Victor Bronshtein, PhD, President, Universal Stabilization Technologies, Inc.
Preservation by vaporization has been demonstrated to be effective and scalable technology for long-term stabilization of active proteins, viruses, and bacteria that could be used as positive controls in diagnostic kits after inactivation by irradiation in the dry state.
12:30 Selected Oral Poster Highlights
1:00 Concluding Remarks, End of Conference
Limited number of speaking slots remains open, if you have suggestions regarding (1) Proposed scope, and/or (2) Potential speakers you’d like to have invited and hear from, do not hesitate to let us know (include contact info for the person you want to be invited to give a talk - Email/Tel).
For potential speakers interested in presenting their latest achievements in this field of R&D, opportunities to speak are available. If you or a colleague are interested in participating as a speaker, we would like to encourage industry, government and academic experts to look into the proposed scope of the meeting and submit a talk proposal for the Program Committee’s consideration (please see below the simple guidelines for mini-abstract submission).
In order to put together the Agenda and publish the conference brochure we need to receive via E-mail:
• Title of your presentation
• Brief description (mini-abstract) - about 80 words long
• Speaker’s title, affiliation and contact info
E-mail your materials to:
Sample Prep East Committee
c/o Knowledge Foundation
(617) 232-7400 ext. 211
To Submit a Presentation Proposal
government and academic scientists are encouraged to submit poster
titles for this event. One-page abstracts (8 1/2" x 11" with 1-inch
margins) must be submitted via e-mail: SUBMIT@knowledgefoundation.com no
later than November 15, 2013 for inclusion in conference
documentation. Additional poster submissions will be accepted until November 25, 2013 but may not be included in conference documentation.
DIMENSIONS of the poster boards are:
4 feet wide by 3 feet high
(although posterboards could be placed vertically as well and
then the dimensions obviously would be 3' w x 4' h, or 90 x 120cm
If you're submitting a poster, you MUST be registered and paid
registration fee plus posterboard reservation fee in advance to ensure
that a posterboard is reserved for you.
includes access to the conference, refreshments, access to posters,
exhibit hall, and all documentation made available to us by speakers.
Sample Prep East
Non-member: US $1099.00
Member: US $934.15
Sample Prep East
Non-member: US $799.00
Member: US $679.15
We accept credit
card payments of Visa, Master Card or American Express through the
online checkout. If making payment by wire transfer or check, all
payments must be made in U.S. funds drawn on a U.S. bank. Please make
check(s) payable to The Knowledge Foundation and attach to the
registration form even if you have registered by phone, fax or e-mail.
To guarantee your registration, payment must be received prior to the
conference. Confirmation of your booking will follow.
Hyatt Regency Cambridge
575 Memorial Drive
Cambridge, MA 02139
A substitute member of your company may replace your
attendance at any time at no charge if you find your schedule prevents
you from attending. Please notify us immediately so that materials can
be prepared. If you do not wish to substitute your registration, we
regret that your cancellation will be subject to a $100 processing fee.
To receive a prompt refund, we must receive your cancellation in writing
30 days prior to the conference. Unfortunately cancellations cannot be
accepted after that date. In the event that The Knowledge Foundation
cancels an event, The Knowledge Foundation cannot resume responsibility
for any travel-related costs.